Rethinking Treatment Goals in Psoriasis: Leveraging IL-17 Inhibitors to Move Beyond Skin Clearance Toward PsA Prevention - Episode 2
Identifying Risk and Recognizing Impact in Psoriatic Disease
In this discussion, the panelists explore the identification of risk factors and the broader impact of psoriatic disease. The experts explain that certain clinical features—such as scalp and nail involvement, higher body surface area, and disease severity—are associated with an increased likelihood of developing psoriatic arthritis (PsA). They also note that modifiable factors like obesity, smoking, and metabolic syndrome further contribute to this risk. While genetics play a role, the experts emphasize the importance of addressing lifestyle factors and systemic inflammation early. The conversation highlights that psoriasis should be recognized as a systemic disease rather than one limited to the skin. By identifying high-risk patients and initiating systemic therapy sooner, clinicians can better manage inflammation, improve quality of life, and potentially reduce PsA progression. The panel underscores the importance of patient education and multidisciplinary care to optimize outcomes.
In this discussion, the panelists explore the identification of risk factors and the broader impact of psoriatic disease. The experts explain that certain clinical features—such as scalp and nail involvement, higher body surface area, and disease severity—are associated with an increased likelihood of developing psoriatic arthritis (PsA). They also note that modifiable factors like obesity, smoking, and metabolic syndrome further contribute to this risk. While genetics play a role, the experts emphasize the importance of addressing lifestyle factors and systemic inflammation early. The conversation highlights that psoriasis should be recognized as a systemic disease rather than one limited to the skin. By identifying high-risk patients and initiating systemic therapy sooner, clinicians can better manage inflammation, improve quality of life, and potentially reduce PsA progression. The panel underscores the importance of patient education and multidisciplinary care to optimize outcomes.
